P Qi1, C-P Ruan, H Wang, F-G Zhou, Y-P Zhao, X Gu, C-F Gao. 1. Department of Laboratory Medicine, Eastern Hepatobiliary Hospital, Second Military Medical University, Shanghai, China.
Abstract
AIM: Colorectal cancer is common, accounting for nearly 10% of all cancers. Transforming growth factor-β1 (TGF-β1) is a pleiotropic cytokine that has been implicated in the pathogenesis of colorectal neoplasia. The most studied -509C>T polymorphism of TGF-β1 gene has been associated with various kinds of cancer. This study investigated the association between this genetic variant and the risk and/or progression of colorectal cancer. METHOD: A case-control study was carried out of 150 colorectal cancer cases and 503 healthy controls. DNA was extracted from blood cell nuclear materials, and -509C>T polymorphism in the TGF-β1 gene promoter was genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Colorectal cancer tissues (n = 70) were obtained from the studied cases for measurement of TGF-β1 mRNA expression levels. We also assessed the plasma TGF-β1 levels of cases (n = 88) and healthy subjects (n = 120). RESULTS: The TGF-β1 producer genotype, -509TT, was not associated with an increased risk of colorectal cancer compared with other genotypes. Colorectal cancer patients especially those with a more aggressive disease behaviour were more frequently associated with C allele. CONCLUSION: The results suggest that TGF-β1 -509C>T polymorphism is not associated with either an increased risk or progression of colorectal cancer.
AIM: Colorectal cancer is common, accounting for nearly 10% of all cancers. Transforming growth factor-β1 (TGF-β1) is a pleiotropic cytokine that has been implicated in the pathogenesis of colorectal neoplasia. The most studied -509C>T polymorphism of TGF-β1 gene has been associated with various kinds of cancer. This study investigated the association between this genetic variant and the risk and/or progression of colorectal cancer. METHOD: A case-control study was carried out of 150 colorectal cancer cases and 503 healthy controls. DNA was extracted from blood cell nuclear materials, and -509C>T polymorphism in the TGF-β1 gene promoter was genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Colorectal cancer tissues (n = 70) were obtained from the studied cases for measurement of TGF-β1 mRNA expression levels. We also assessed the plasma TGF-β1 levels of cases (n = 88) and healthy subjects (n = 120). RESULTS: The TGF-β1 producer genotype, -509TT, was not associated with an increased risk of colorectal cancer compared with other genotypes. Colorectal cancerpatients especially those with a more aggressive disease behaviour were more frequently associated with C allele. CONCLUSION: The results suggest that TGF-β1 -509C>T polymorphism is not associated with either an increased risk or progression of colorectal cancer.
Authors: Joana Vieira de Castro; Céline S Gonçalves; Sandra Costa; Paulo Linhares; Rui Vaz; Ricardo Nabiço; Júlia Amorim; Marta Viana-Pereira; Rui M Reis; Bruno M Costa Journal: Tumour Biol Date: 2015-03-27